Gastrazole

Gastrazole (JB95008) is potent and selective CCK2/gastrin receptor antagonist. Gastrazole can decrease the level of gastric acid. Gastrazole inhibits the Gastrin-stimulated growth of pancreatic cancer[1][2].

Product Specifications

CAS Number

[862583-15-1]

Product Name Alternative

JB95008

UNSPSC

12352005

Target

Cholecystokinin Receptor

Type

Reference compound

Related Pathways

GPCR/G Protein; Neuronal Signaling

Applications

Cancer-programmed cell death

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/gastrazole.html

Solubility

10 mM in DMSO

Smiles

O=C(C(C=C(NC=N1)C1=C2)=C2C(NCC3CCCCCC3)=O)N[C@H](C(NC4=CC(C(O[Na])=O)=CC(C(O[Na])=O)=C4)=O)CC(C=CC=C5)=C5F

Molecular Formula

C34H32FN5Na2O7

Molecular Weight

687.63

References & Citations

[1]Chau I, et, al. Gastrazole (JB95008), a novel CCK2/gastrin receptor antagonist, in the treatment of advanced pancreatic cancer: results from two randomised controlled trials. Br J Cancer. 2006 Apr 24;94 (8) :1107-15.|[2]Rudholm T, et, al. Release of regulatory gut peptides somatostatin, neurotensin and vasoactive intestinal peptide by acid and hyperosmolal solutions in the intestine in conscious rats. Regul Pept. 2009 Jan 8;152 (1-3) :8-12.